Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28677080 | 0.91 | OPRM1 (0.48) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| SCHEMBL2256573 | 0.83 | OPRM1 (0.67) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| SCHEMBL2256575 | 0.83 | OPRM1 (0.67) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| Ammonia Solution, Strong SCHEMBL1158702 | 0.80 | OPRM1 (0.64) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| Bromide SCHEMBL28969840 | 0.80 | OPRM1 (0.64) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| Iodide SCHEMBL28805522 | 0.78 | OPRM1 (0.61) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| SCHEMBL8772674 | 0.78 | OPRM1 (0.61) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| Bromide SCHEMBL28680754 | 0.78 | OPRM1 (0.61) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| SCHEMBL827795 | 0.78 | OPRM1 (0.61) | OPRM1MEN1CYP2C9KMT2AGRIN2D | |
| SCHEMBL24157288 | 0.76 | ESR1 (0.58) | OPRM1MEN1CYP2C9KMT2AGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1298390-C | Smulaneous imaging of cardiac perfusion and vitronection receptor targeted imaging agent | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-02-07 | — | — | CN | claimed |
| US-8802634-B2 | CD40-L Inhibitory Peptides | PHYLOGICA LIMITED (AU) | 2014-08-12 | — | — | US | disclosed |
| US-20130266605-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | PHYLOGICA LIMITED (AU) | 2013-10-10 | — | — | US | disclosed |
| EP-2616480-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | Phylogica Limited (AU) | 2013-07-24 | — | — | EP | disclosed |
| US-8394356-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130022590-A1 | Compositions Comprising Zinc Finger Domains and Uses Therefor | THE UNIVERSITY OF SYDNEY (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| CN-101432923-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP | 2012-04-18 | — | — | CN | disclosed |
| WO-2012034188-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | PHYLOGICA LIMITED (AU) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065134-A1 | CD40-L INHIBITORY PHYLOMER PEPTIDES | PHYLOGICA LIMITED (AU) | 2012-03-15 | — | — | US | disclosed |
| US-7011815-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040202613-A1 | Chelate compounds | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-6676929-B2 | MEDICAL DIAGNOSIS; GADOFOSVESET | EPIX MEDICAL, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030180223-A1 | Magnetic resonance imaging | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003029257-A1 | (ETHYLENE)-(PROPENE/BUTENE)-PHOSPHODIESTER TRIAMINE PENTAACETIC ACID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | WO | disclosed |
| US-20020164289-A1 | Medical diagnosis | CITIZENS BANK, N.A. | 2002-11-07 | — | — | US | disclosed |
| EP-0806968-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | Epix Medical, Inc. (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023526-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | EPIX MEDICAL, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| US-4673724-A | FROM P-OXYBENZOYL AND 2-OXY-6-NAPHTHOYL COMPOUND | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1987-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164289-A1 | Medical diagnosis | FABP1, B2M, MB | OPRM1 714/4885MEN1 587/4885CYP2C9 3830/4885 |
| US-20030180223-A1 | Magnetic resonance imaging | BHMT, FABP1, FABP7 | OPRM1 887/4885MEN1 807/4885CYP2C9 4385/4885 |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | FABP1, BHMT, FABP3 | OPRM1 664/4885MEN1 806/4885CYP2C9 2921/4885 |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | FABP1, B2M, BHMT | OPRM1 1082/4885MEN1 577/4885CYP2C9 4039/4885 |
| US-20040202613-A1 | Chelate compounds | FABP1, BHMT, FABP3 | OPRM1 877/4885MEN1 966/4885CYP2C9 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.